{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:06:59Z","timestamp":1792728419848,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    Atherosclerosis is a chronic metabolic disorder driven by endothelial dysfunction, inflammation, oxidative stress, and progressive plaque remodeling; processes amplified in type 2 diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for glycemic control, have emerged as modulators of vascular biology with potential anti-atherosclerotic effects. This review synthesizes evidence across key mechanistic domains, including endothelial dysfunction, inflammatory signaling, oxidative stress pathways, plaque biology, extracellular matrix remodeling, and immune-cell modulation. GLP-1RAs reduce circulating inflammatory mediators, suppress NLRP3 inflammasome activity, and lower oxidized LDL, thereby limiting the initiation of vascular injury. At the endothelial level, they enhance nitric oxide (NO) availability, decrease NOX-derived oxidative stress, and reduce adhesion molecule expression, collectively improving vascular function. Within plaques, GLP-1RA signaling alters macrophage behavior, promotes cholesterol efflux, and modulates metalloproteinase activity, suggesting potential effects on plaque composition and stability. Emerging biomarker platforms, including microRNA profiling and high-throughput proteomic and lipidomic signatures, together with advanced imaging approaches such as MRI-visible nano-GLP-1RA formulations, provide novel tools to monitor molecular and spatial drug effects\n                    <jats:italic>in vivo<\/jats:italic>\n                    . Collectively, these findings position GLP-1RAs as modulators of atherosclerotic disease beyond glycemic control, with integrated effects spanning systemic immunometabolism and plaque biology. By linking mechanistic insights with emerging imaging and multi-omics technologies, this review highlights a path toward biomarker-driven patient stratification and precision cardiovascular therapeutics, redefining how vascular risk is assessed and treated in metabolic disease.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2026.1813873","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:28:41Z","timestamp":1778732921000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of glucagon-like peptide-1 receptor agonists in type 2 diabetes-associated atherosclerosis: from vascular mechanism to omics-based biomarkers and imaging"],"prefix":"10.3389","volume":"13","author":[{"given":"Raghad","family":"Al-Taweel","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University","place":["Doha, Qatar"]},{"name":"Biomedical Research Centre, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Malki","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/B978-0-443-19116-9.00036-1","article-title":"Atherosclerosis and inflammation","volume-title":"Lipid Analysis in Biology, Health, and Disease","author":"Almobayed","year":"2026"},{"key":"B2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1124\/pharmrev.120.000096","article-title":"Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies","volume":"73","author":"Xu","year":"2021","journal-title":"Pharmacol Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2218684","DOI":"10.1080\/13510002.2023.2218684","article-title":"Liraglutide ameliorates oxidized LDL-induced endothelial dysfunction by GLP-1R-dependent downregulation of LOX-1-mediated oxidative stress and inflammation","volume":"28","author":"Ying","year":"2023","journal-title":"Redox Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"9977","DOI":"10.3390\/ijms26209977","article-title":"GLP-1 receptor agonists are associated with reduced ascending aorta dilatation in patients with type 2 diabetes: a prospective study","volume":"26","author":"Sardu","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.3390\/ijms25031854","article-title":"Impact of glucagon-like peptide 1 receptor agonists on biochemical markers of the initiation of atherosclerotic process","volume":"25","author":"Hachu\u0142a","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40256-024-00647-3","article-title":"Cardiovascular benefits of GLP-1 receptor agonists in patients living with obesity or overweight: a meta-analysis of randomized controlled trials","volume":"24","author":"de Oliveira Almeida","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"102849","DOI":"10.1016\/j.redox.2023.102849","article-title":"Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte\u2013endothelium interactions in type 2 diabetes","volume":"66","author":"Luna-Marco","year":"2023","journal-title":"Redox Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2478\/jtim-2022-0012","article-title":"Inflammatory factors driving atherosclerotic plaque progression new insights","volume":"10","author":"Song","year":"2022","journal-title":"J Transl Int Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5245308","DOI":"10.1155\/2020\/5245308","article-title":"Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis","volume":"2020","author":"Khatana","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1253\/circj.CJ-16-0924","article-title":"Macrophage apoptosis and efferocytosis in the pathogenesis of atherosclerosis","volume":"80","author":"Linton","year":"2016","journal-title":"Circ J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.jacc.2018.11.054","article-title":"The interleukin-1 axis and risk of death in patients with acutely decompensated heart failure","volume":"73","author":"Pascual-Figal","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11926-012-0313-z","article-title":"Cholesterol crystals and inflammation","volume":"15","author":"Grebe","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11883-017-0678-6","article-title":"Oxidative stress in atherosclerosis","volume":"19","author":"Kattoor","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/life14060690","article-title":"Effect of GLP-1RA treatment on adhesion molecules and monocyte chemoattractant protein-1 in diabetic patients with atherosclerosis","volume":"14","author":"Hachu\u0142a","year":"2024","journal-title":"Life (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.113.301086","article-title":"Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice","volume":"112","author":"Westerterp","year":"2013","journal-title":"Circ Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.7150\/thno.66456","article-title":"Plaque-targeted, proteolysis-resistant, activatable and MRI-visible nano-GLP-1 receptor agonist targets smooth muscle cell differentiation in atherosclerosis","volume":"12","author":"Maiseyeu","year":"2022","journal-title":"Theranostics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7047","DOI":"10.2147\/JIR.S524495","article-title":"The association between high-sensitivity C-reactive protein and the progression of arteriosclerosis: the Kailuan study","volume":"18","author":"Li","year":"2025","journal-title":"J Inflamm Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7580","DOI":"10.1038\/s41598-023-34642-6","article-title":"Associations between circulating microRNAs and lipid-rich coronary plaques measured with near-infrared spectroscopy","volume":"13","author":"S\u00e6ther","year":"2023","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molmed.2015.02.003","article-title":"Mirnas in atherosclerotic plaque initiation, progression, and rupture","volume":"21","author":"Andreou","year":"2015","journal-title":"Trends Mol Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1124\/jpet.121.001152","article-title":"The role of microRNA in the development, diagnosis, and treatment of cardiovascular disease: recent developments","volume":"384","author":"Wronska","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/eurheartj\/ehad161","article-title":"Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction","volume":"44","author":"Nurmohamed","year":"2023","journal-title":"Eur Heart J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s00018-020-03715-4","article-title":"Integrating lipidomics and genomics: emerging tools to understand cardiovascular diseases","volume":"78","author":"Tabassum","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s44325-025-00091-5","article-title":"Characterizing lipoprotein profiles in coronary atherosclerosis development through quantitative lipidomics and proteomics approaches","volume":"2","author":"Takeda","year":"2025","journal-title":"npj Cardiovasc Health"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","article-title":"Aptamer-based multiplexed proteomic technology for biomarker discovery","volume":"5","author":"Gold","year":"2010","journal-title":"Nat Prec"},{"key":"B25","doi-asserted-by":"publisher","first-page":"8382","DOI":"10.1038\/s41598-018-26640-w","article-title":"Stability and reproducibility of proteomic profiles measured with an aptamer-based platform","volume":"8","author":"Kim","year":"2018","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41591-024-03355-2","article-title":"Proteomic changes upon treatment with semaglutide in individuals with obesity","volume":"31","author":"Maretty","year":"2025","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3724\/abbs.2024150","article-title":"Soluble (pro)renin receptor as a novel laboratory biomarker of atherosclerosis","volume":"57","author":"Liu","year":"2025","journal-title":"Acta Biochim Biophys Sin (Shanghai)"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1813873\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:28:45Z","timestamp":1778732925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1813873\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":27,"alternative-id":["10.3389\/fcvm.2026.1813873"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1813873","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1813873"}}